Cardiovascular Comorbidities of Psoriasis and Psoriatic Arthritis: A Report from the GRAPPA 2012 Annual Meeting
Cardiovascular Comorbidities of Psoriasis and Psoriatic Arthritis: A Report from the GRAPPA 2012 Annual Meeting
复制标题
DOI：
10.3899/jrheum.130457
复制
发表时间：
2013-08-01
影响因子：
3.9
通讯作者：
Armstrong, Ehrin J.
中科院分区：
文献类型：
--
作者：
Armstrong, April W.;Gelfand, Joel M.;Armstrong, Ehrin J.
在瑞典斯德哥尔摩举行的银屑病和银屑病关节炎研究和评估小组（GRAPPA）2012年年会上，GRAPPA的几位成员领导了关于银屑病和银屑病关节炎（PsA）的心血管（CV）合并症的小组讨论。小组成员讨论了胰岛素抵抗在银屑病病理生理学中的作用、肿瘤坏死因子抑制剂对CV合并症的可能影响以及12/23种单克隆抗体对CV结局的影响。小组成员还讨论了如何将CV合并症研究的经验教训应用于银屑病和PsA合并症研究的其他领域，并确定了该领域未来的研究方向。
At the 2012 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) in Stockholm, Sweden, several GRAPPA members led a panel discussion on cardiovascular (CV) comorbidities of psoriasis and psoriatic arthritis (PsA). The panelists discussed the role of insulin resistance in the pathophysiology of psoriasis, the possible effect of tumor necrosis factor inhibitors on CV comorbidities, and the effect of 12/23 monoclonal antibodies on CV outcomes. The panelists also addressed how lessons from CV comorbidity research could be applied to other areas of comorbidity research in psoriasis and PsA and identified future research directions in this area.